| Trial ID: | L6607 |
| Source ID: | NCT04240171
|
| Associated Drug: |
Dapagliflozin 5mg Tab
|
| Title: |
Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Dapagliflozin 5Mg Tab|DRUG: Glimepiride 4Mg Tab
|
| Outcome Measures: |
Primary: Blood Sugar (mg/dl), serum blood glucose, three months|HbA1c %, Glycated Hemoglobin, three months | Secondary: NT-Pro BNP (ng/ml), Natriuretic peptide tests measure levels of BNP or NT-proBNP in the blood., Three Months|IRAPe (ng/ml), extracellular part of insulin-regulated aminopeptidase (IRAPe)., Three Months|IL-34 (pg./ml), interleukin (IL)-34., Three Months
|
| Sponsor/Collaborators: |
Sponsor: Damanhour University | Collaborators: Tanta University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
60
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2020-12-01
|
| Completion Date: |
2022-01-31
|
| Results First Posted: |
|
| Last Update Posted: |
2023-04-18
|
| Locations: |
Tanta University Hospital, Tanta, El-Gharbia, 31527, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT04240171
|
